Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?
09:00am, Wednesday, 21'st Feb 2024
Bristol Myers Squibb BMY (NYSE: BMY) reported its Q4 results earlier this month, with revenues and earnings beating the street estimates. The company reported revenue of $11.5 billion and adjusted ear
The 3 Best Stocks Beginning Investors Can Buy: February 2024
08:04am, Wednesday, 21'st Feb 2024
Picking the best stocks for beginning investors is crucial as they enter the world of long-term investing. With a myriad of options available, it's essential to focus on stocks that offer growth poten
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
08:30am, Saturday, 17'th Feb 2024
Pfizer and Bristol Myers Squibb have delivered poor financial results of late. Some investors might worry about the future of their dividend programs.
February's 5 Dividend Growth Stocks With 4.75%+ Yields
07:08am, Saturday, 17'th Feb 2024
Every month we look at companies that are delivering not only a solid dividend yield but also showing a trend of growing dividends. Companies that can consistently deliver dividend growth due to risin
A Look at Pharma ETFs After Q4 Earnings
02:01pm, Monday, 12'th Feb 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs re
New Strong Sell Stocks for February 12th
07:06am, Monday, 12'th Feb 2024
ACLS, BMY and CHX have been added to the Zacks Rank #5 (Strong Sell) List on February 12, 2023.
7 Biotech Stocks Fighting America's Deadliest Diseases
04:10pm, Thursday, 08'th Feb 2024
Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.
J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemen
03:29pm, Thursday, 08'th Feb 2024
Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.
US Senate Democrats grill pharma CEOs on drug prices
03:18pm, Thursday, 08'th Feb 2024
U.S. Senate Democrats grilled three top pharmaceutical executives over the high cost of prescription drugs on Thursday but failed to extract any commitments from them to lower prices.
Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted
11:35am, Thursday, 08'th Feb 2024
Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
11:31am, Thursday, 08'th Feb 2024
JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch For
10:28am, Thursday, 08'th Feb 2024
Chief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders (I-Vt.
Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing
07:00am, Thursday, 08'th Feb 2024
The push to cut drug prices is one of those rare hot-button issues that unites the two major political parties.
Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radar
02:08pm, Wednesday, 07'th Feb 2024
Lawmakers seeking to hold drugmakers accountable for high prescription-drug costs are focusing on some prices that shed little light on the problem, drug-pricing experts say.
3 Blue-Chip Stocks to Buy at a 52-Week Low in February
01:40pm, Wednesday, 07'th Feb 2024
It's tough to make the argument that stocks are cheap. But it's still possible to find some value.
